Home

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revision Previous revision
home:food:aim_health:aging [02.25.2019]
sallieq [A number of studies have found]
home:food:aim_health:aging [03.13.2019] (current)
sallieq [with additional studies]
Line 15: Line 15:
  
  ​Benefits of RAS blockade with olmesartan treatment are sustained after study discontinued. ​ (({{pubmed>​long:​24772521}}))  ​Benefits of RAS blockade with olmesartan treatment are sustained after study discontinued. ​ (({{pubmed>​long:​24772521}}))
 +
 +Olmesartan and Bay11-7082 inhibit the MCF-7 cells growth indicating RAS and NF-kappaB pathway blockade lead to cytotoxicity and apoptosis induction against tumour cells. ​  (in breast cancer)(({{pubmed>​long: ​   26138656}}))
  
 Data demonstrate potential benefits of reducing the heart rate of type 2 diabetes patients, and indicate that olmesartan could, in particular, reduce the risk of microalbuminuria in patients with low heart rate. (({{pubmed>​long:​27082551}})) ​ Data demonstrate potential benefits of reducing the heart rate of type 2 diabetes patients, and indicate that olmesartan could, in particular, reduce the risk of microalbuminuria in patients with low heart rate. (({{pubmed>​long:​27082551}})) ​
home/food/aim_health/aging.txt · Last modified: 03.13.2019 by sallieq
© 2015, Autoimmunity Research Foundation. All Rights Reserved.